CARM1 Inhibition Reduces Histone Acetyltransferase Activity Causing Synthetic Lethality In CREBBP/EP300-Mutated Lymphomas

02 Jul, 2020 ,

Kylee J. Veazey conducted a study to assess the effect of CARM1 inhibition in reducing histone acetyltransferase activity that causes synthetic lethality in CREBBP/EP300-mutated lymphomas. The researches concluded that CARM1i further reduces the histone acetyltransferase activity of CBP genome wide and downregulates CBP-target genes in DLBCL cells, resulting in a synthetic lethality that leverages the mutational status of CREBBP/EP300 as a biomarker for the use of small-molecule inhibitors of CARM1 in DLBCL and other cancers.